ncRNA basic information ncRNA ID: MI0000434 ncRNA Database: miRBase ncRNA Name: let-7i ncRNA Type: miRNA ncRNA Expression: down-regulated ncRNA Method: qRT-PCR ncRNA Target Gene: ST3GAL IV ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00619 (APRD01028, EXPT02967, DB03261) Drug Name: Imatinib Drug Method: In current study we initially explored N-glycan profiles on the surface of CML cell lines and bone marrow mononuclear cells (BMMC) of CML patients by using mass spectrometry (MS) analysis. An elevated sialylation was detected in K562R cells (CML cells with imatinib resistance phenotype) compare to K562 cells. By quantitative real time-PCR (qRT-PCR) and western blotting analysis we observed that imatinib resistant K562R cells exhibited marked high levels of CMP-N-acetylneuraminate-Beta-galactosamide-alpha-2,3-sialyltransferase (ST3Gal IV) as compared to imatinib sensitive K562 cells. Further studies revealed that manipulated expression of ST3GAL IV led to the significant alterations of cell cycle distribution, apoptotic signal, cell proliferation and the effectiveness of imatinib treatment. Using microRNA array, miRNA database searching and luciferase reporter assay, we identified that miR-224 and let-7i directly regulate the expression of ST3GAL IV gene. Moreover, engineered expression of miR-224 and let-7i in K562 and K562R cells could significantly affect ST6Gal IV-induced proliferation rate and drug-resistance. Drug Response: resistant

Cancer basic information Cancer: chronic myeloid leukemia Tissue/Cell: cell line ( K562, K562R)

Other information Title: Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression. Journal: Gene Published: 2017 PubMed ID: 28512058